Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]) Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)

Description

List of Tables

Europe Cancer Diagnostics Market by Product (IVD [Microarray, Immunoassay, PCR, Sequencing], Imaging [CT, MRI, Mammography, Ultrasound]), Cancer Type (Breast, Lung, Colon, Prostate), End User (Hospital, Imaging Center, Pharmaceutical)-Global Forecast to 2031.

The Europe cancer diagnostics market is projected to reach $12.21 billion by 2031, at a CAGR of 5.6% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report analyzes key industry drivers, restraints, challenges, and opportunities. The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, and increasing investments and funding for cancer research. Additionally, the supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market.

However, the high cost of imaging systems restrains the growth of this market. Additionally, the lack of skilled professionals and insufficiencies in the implementation of cancer screening programs pose a significant challenge to the market's growth.

Among the products, in 2024, the IVD segment is expected to account for the largest share of the Europe cancer diagnostics market. IVD instruments provide precise, reliable screening and diagnostic testing through simple workflows and integrated software. Furthermore, IVD consumables assist healthcare providers in obtaining vital information regarding genetic abnormalities, tumor markers, and other diagnostic indicators to monitor disease development, guide treatment decisions, and assess therapy responses in cancer patients. The large market share of this segment is attributed to the advancements in IVD technology, the commercial availability of a diverse range of IVD reagents & consumables for the diagnosis of cancer, and the recurring use of IVD consumables.

Among the cancer types, in 2024, the breast cancer segment is expected to account for the largest share of the Europe cancer diagnostics market. The increase in breast cancer cases, increasing healthcare expenditure, and inclusion of certain advanced technologies such as NGS in the reimbursement have propelled the demand for cancer diagnostics for breast cancer. Additionally, government initiatives promoting breast cancer awareness regarding diagnosis and treatment boost breast cancer diagnosis. For instance, in October 2023, Galderma SA (Switzerland) launched a new breast cancer campaign called 'Facing Breast Cancer Together', this campaign focuses on providing support and education about breast cancer awareness. Galderma has partnered with the National Breast Cancer Foundation (NBCF) to promote breast cancer awareness.

Among the end users, in 2024, the hospitals & diagnostic laboratories segment is expected to account for the largest share of the Europe cancer diagnostics market. The large market share of this segment is attributed to the increasing cancer cases, the higher purchasing power of hospitals and diagnostic laboratories, well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, ease in accessibility, better health coverage for hospital-based healthcare services from various private & group insurance plans, and the increasing number of hospitals and expansion of diagnostic laboratories.

An in-depth analysis of the Europe cancer diagnostics market provides detailed qualitative and quantitative insights into major countries, namely Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe. In 2023, Germany is estimated to account for the largest share of the Europe cancer diagnostics market. The market growth in Germany is attributed to the increasing prevalence of cancer, the high adoption of advanced technologies, the established healthcare systems, rising healthcare expenditures, increasing investments and funding for cancer research, and initiatives to raise awareness about cancer diagnosis.

Some of the key players operating in the Europe Cancer Diagnostics market report are F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Abbott Laboratories (U.S.), Illumina, Inc. (U.S.), Siemens Healthineers AG (Germany), GE HealthCare Technologies Inc. (U.S.), Koninklijke Philips N.V (Netherlands), FUJIFILM Holdings Corporation (Japan), Canon Medical Systems Corporation (a subsidiary of Canon Inc.) (Japan), and Hologic, Inc. (U.S.).

Scope of the Report:

Europe Cancer Diagnostics Market Size & Trend Analysis-by Product

In Vitro Diagnostics

IVD Consumables

Kits & Assays
Reagents
- IVD Instruments
Polymerase Chain Reaction (PCR) Systems
Microarray Readers
Immunoassay Analyzers
Sequencers
Other IVD Instruments
- IVD Software & Services

(Other IVD instruments include in-situ hybridization, hematology analyzers, and clinical chemistry analyzers)

Diagnostic Imaging

Imaging Instruments

Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Mammography
Ultrasound
Other Imaging Instruments

(Other imaging instruments include Positron Emission Tomography (PET) and X-ray)

Imaging Consumables

Contrast Agents
Syringes and Injectors
Contrast Delivery Systems
Skin Markers
Phantoms
Other Imaging Consumables

(Other imaging consumables include films, gels, transducers, and probes, among others)

Imaging Software and Services

Europe Cancer Diagnostics Market Size & Trend Analysis-by Cancer Type

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Other Cancer Type

Note: Other cancer types include leukemia, lymphoma, stomach, ovarian, melanoma, kidney, and cervical cancers.

Europe Cancer Diagnostics Market Size & Trend Analysis-by End User

Hospital & Diagnostics Laboratories
Diagnostic Imaging Centers
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes

Europe Cancer Diagnostics Market Size & Trend Analysis-by Country

Germany
France
Italy
U.K.
Spain
Switzerland
Netherlands
Rest of Europe

Product Code: MRHC - 1041104

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Process
2.2. Process of Data Collection & Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and forecast
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Factors Affecting Market Growth
- 4.2.1. Market Dynamics
  - 4.2.1.1. Rising Cancer Prevalence Coupled with Technological Advancements Fueling the Market Growth
  - 4.2.1.2. Supporting Initiatives for Early Cancer Diagnosis and Creating Awareness Driving the Market Growth
  - 4.2.1.3. Growing Adoption and Supporting Initiatives for Precision Cancer Diagnostics Creating Opportunities for the Market Players
  - 4.2.1.4. Insufficiencies in the Implementation of Cancer Screening Programs: A Challenge for Cancer Diagnosis in Europe
- 4.2.2. Factor Analysis
4.3. Trends
4.4. Regulatory Analysis
- 4.4.1. Regulatory Analysis for IVD Technologies
- 4.4.2. Regulatory Analysis for Diagnostic Imaging Devices
4.5. Porter's Five Forces Analysis: Diagnostic Imaging Technologies for Cancer Screening
- 4.5.1. Bargaining Power of Buyers
- 4.5.2. Bargaining Power of Suppliers
- 4.5.3. Threat of Substitutes
- 4.5.4. Threat of New Entrants
- 4.5.5. Degree of Competition
4.6. Porter's Five Forces Analysis: IVD Technologies for Cancer Screening
- 4.6.1. Bargaining Power of Buyers
- 4.6.2. Bargaining Power of Suppliers
- 4.6.3. Threat of Substitutes
- 4.6.4. Threat of New Entrants
- 4.6.5. Degree of Competition
4.7. Pricing Analysis

5. Europe Cancer Diagnostics Market-by Product

5.1. Overview
5.2. In Vitro Diagnostics
- 5.2.1. IVD Consumables
  - 5.2.1.1. Kits & Assays
  - 5.2.1.2. Reagents
- 5.2.2. IVD Instruments
  - 5.2.2.1. Sequencers
  - 5.2.2.2. Polymerase Chain Reaction (PCR) Systems
  - 5.2.2.3. Immunoassay Analyzers
  - 5.2.2.4. Microarray Readers
  - 5.2.2.5. Other IVD Instruments
- 5.2.3. IVD Software & Services
5.3. Diagnostic Imaging
- 5.3.1. Imaging Instruments
  - 5.3.1.1. Computed Tomography (CT)
  - 5.3.1.2. Mammography
  - 5.3.1.3. Magnetic Resonance Imaging (MRI)
  - 5.3.1.4. Ultrasound
  - 5.3.1.5. Other Imaging Instruments
- 5.3.2. Imaging Consumables
  - 5.3.2.1. Contrast Agents
  - 5.3.2.2. Syringes & Injectors
  - 5.3.2.3. Contrast Delivery Systems
  - 5.3.2.4. Skin Markers
  - 5.3.2.5. Phantoms
  - 5.3.2.6. Other Imaging Consumables
- 5.3.3. Imaging Software & Services

6. Europe Cancer Diagnostics Market-by Cancer Type

6.1. Overview
6.2. Breast Cancer
6.3. Lung Cancer
6.4. Colorectal Cancer
6.5. Prostate Cancer
6.6. Other Cancer Types

7. Europe Cancer Diagnostics Market-by End User

7.1. Overview
7.2. Hospitals & Diagnostic Laboratories
7.3. Diagnostic Imaging Centers
7.4. Pharmaceutical & Biotechnology Companies
7.5. Academic & Research Institutes

8. Europe Cancer Diagnostics Market Assessment- by Geography

8.1. Overview
8.2. Germany
8.3. France
8.4. U.K.
8.5. Italy
8.6. Spain
8.7. Switzerland
8.8. Netherlands
8.9. Rest of Europe (RoE)

9. Competition Analysis

9.1. Overview
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2023)
- 9.4.1. Europe Cancer IVD Market Share Analysis (2023)
  - 9.4.1.1. F. Hoffmann-La Roche Ltd (Switzerland)
  - 9.4.1.2. Thermo Fisher Scientific Inc. (U.S.)
  - 9.4.1.3. Illumina, Inc. (U.S.)
- 9.4.2. Europe Diagnostic Imaging Market Share Analysis (2023)
  - 9.4.2.1. GE Healthcare Technologies Inc. (U.S.)
  - 9.4.2.2. Siemens Healthineers AG (Germany)
  - 9.4.2.3. Hologic, Inc. (U.S.)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments, SWOT Analysis)

10.1. F. Hoffmann-La Roche Ltd
10.2. Thermo Fisher Scientific Inc.
10.3. QIAGEN N.V.
10.4. Abbott Laboratories
10.5. Illumina, Inc.
10.6. Siemens Healthineers AG
10.7. GE Healthcare Technologies Inc.
10.8. Hologic, Inc.
10.9. Koninklijke Philips N.V.
10.10. Fujifilm Holdings Corporation
10.11. Canon Medical Systems Corporation

(Note: SWOT Analysis of the Top 6 Companies Will Be Provided)

11. Appendix

11.1. Related Reports